journal
MENU ▼
Read by QxMD icon Read
search

Clinical Advances in Hematology & Oncology: H&O

journal
https://read.qxmd.com/read/30543591/growing-my-practice-keeping-up-with-medical-knowledge-and-handling-adverse-outcomes
#1
Sundhar Ramalingam
No abstract text is available yet for this article.
November 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543590/novel-therapeutic-approaches-in-polycythemia-vera
#2
REVIEW
Charles Elliott Foucar, Brady Lee Stein
Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm. Whereas low-risk patients are treated with aspirin and phlebotomy, high-risk patients receive cytoreductive therapy, which most commonly consists of hydroxyurea in the United States. Concerns about the long-term safety of hydroxyurea, as well as a desire for more efficacious and targeted therapy, have led to the development of novel therapies for high-risk patients with PV. Pegylated interferon (IFN) has shown promise in phase 2 studies of PV, and preliminary data from ongoing phase 3 studies suggest noninferiority as a frontline therapy...
November 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543589/microsatellite-instability-in-colorectal-cancer-overview-of-its-clinical-significance-and-novel-perspectives
#3
REVIEW
Francesca Battaglin, Madiha Naseem, Heinz-Josef Lenz, Mohamed E Salem
Microsatellite instability (MSI) is a key biomarker in colorectal cancer (CRC), with crucial diagnostic, prognostic, and predictive implications. Testing for mismatch repair deficiency (MMR-D)/MSI is recommended during screening for Lynch syndrome, an autosomal-dominant hereditary disease that is characterized by germline mutations in the MMR genes and associated with an increased risk for several types of cancer. Additionally, MSI-high (MSI-H) status is associated with a better prognosis in early-stage CRC and a lack of benefit from adjuvant treatment with 5-fluorouracil in stage II disease...
November 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543588/loncastuximab-tesirine-in-patients-with-b-cell-non-hodgkin-lymphoma
#4
Brad S Kahl
No abstract text is available yet for this article.
November 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543587/the-role-of-the-nci-investigational-drug-branch
#5
Jeff Moscow
No abstract text is available yet for this article.
November 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543586/the-role-of-her2-amplification-testing-in-metastatic-colorectal-cancer
#6
Kanwal P S Raghav
No abstract text is available yet for this article.
November 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543585/new-paradigms-and-therapies-for-iron-replacement-in-iron-deficiency-anemia
#7
Michael Auerbach
No abstract text is available yet for this article.
November 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543584/hem-onc-news
#8
Devon Schuyler
No abstract text is available yet for this article.
November 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543598/evolving-landscape-of-the-treatment-of-metastatic-clear-cell-renal-cell-carcinoma
#9
REVIEW
Pooja Ghatalia, Matthew R Zibelman, Daniel M Geynisman, Elizabeth R Plimack
The management of advanced clear cell renal cell carcinoma (RCC) has evolved over the past decade with the introduction of targeted therapies and immune checkpoint inhibitors. Recently, studies of dual checkpoint inhibition and of vascular endothelial growth factor (VEGF) inhibition combined with checkpoint inhibition have shown promising results, adding newer options to the treatment armamentarium for advanced RCC. Specifically, therapies combining checkpoint inhibitors of different classes and combining VEGF inhibitors with checkpoint inhibitors have gained much interest, and results from studies of several other combinations are awaited...
October 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543597/immune-mediated-hemolytic-anemia-and-thrombocytopenia-in-clonal-b-cell-disorders-a-review
#10
REVIEW
Urshila Durani, Ronald S Go, Neil E Kay
Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia purpura (ITP) have been associated with B-cell lymphoproliferative disorders. Here, we review the epidemiology, pathogenesis, diagnosis, and treatment of these autoimmune disorders, specifically in the setting of B-cell malignancies. AIHA and ITP are classically associated with chronic lymphocytic leukemia (CLL) but have also been reported in plasmacytic and lymphoproliferative disorders. AIHA includes both warm AIHA and cold agglutinin disease, the latter of which is strongly associated with Waldenström macroglobulinemia...
October 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543596/a-closer-look-at-regorafenib
#11
Tanios Bekaii-Saab
No abstract text is available yet for this article.
October 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543595/tisagenlecleucel-in-pediatric-patients-with-acute-lymphoblastic-leukemia
#12
Shannon L Maude
No abstract text is available yet for this article.
October 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543594/management-of-epithelial-ovarian-cancer
#13
Mario M Leitao
No abstract text is available yet for this article.
October 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543593/ethical-issues-in-the-development-of-oncology-drugs
#14
Jonathan Kimmelman
No abstract text is available yet for this article.
October 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30543592/hem-onc-news
#15
Devon Schuyler
No abstract text is available yet for this article.
October 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30256778/distinguishing-autoimmune-myelofibrosis-from-primary-myelofibrosis
#16
REVIEW
Bridget Marcellino, Siraj M El Jamal, John O Mascarenhas
Bone marrow fibrosis (BMF) is a histologic finding in a wide range of diseases, including malignancies, endocrine disorders, autoimmune diseases, and infections. Autoimmune myelofibrosis (AIMF) is an uncommon etiology of BMF; it can be secondary to a defined autoimmune disease, or it can be primary in the absence of a clinically diagnosed autoimmune disease but the presence of serologic evidence of autoantibodies. Distinguishing between primary myelofibrosis (PMF) and non-neoplastic AIMF is of the utmost importance because the prognosis and therapeutic options are different...
September 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30256777/changing-local-therapy-in-breast-cancer-who-needs-what-and-when
#17
REVIEW
Batul H Al-Zubeidy, Hannah Weiss, Seema A Khan
The local therapy of breast cancer continues to evolve toward less surgery. Breast conservation is firmly in place, with recent trends toward decreased rates of re-excision. Axillary dissection is becoming a rare operation and is being replaced by sentinel node biopsy. The switch to sentinel node biopsy occurred first in patients with pathologically tumor-free nodes, and later in patients with limited nodal disease. Sentinel node biopsy is now also widely used in patients with pathologically positive nodes who receive neoadjuvant chemotherapy...
September 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30256776/dosing-drugs-in-elderly-patients-with-cancer
#18
Arti Hurria
No abstract text is available yet for this article.
September 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30256775/diagnosis-and-management-of-dysfibrinogenemia
#19
Susan E Shapiro
No abstract text is available yet for this article.
September 2018: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/30256774/update-on-managing-brain-metastases-in-breast-cancer
#20
Nancy U Lin
No abstract text is available yet for this article.
September 2018: Clinical Advances in Hematology & Oncology: H&O
journal
journal
40386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"